Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23655363 | 0.88 | ALDH1A1 (0.46) | ALDH1A1GAAPOLBPABPC1PIK3CD | |
| SCHEMBL16462653 | 0.86 | ALDH1A1 (0.48) | ALDH1A1GAAPOLBPABPC1PIK3CD | |
| SCHEMBL16462409 | 0.86 | ALDH1A1 (0.48) | ALDH1A1GAAPOLBPABPC1PIK3CD | |
| SCHEMBL17810131 | 0.81 | APP (0.32) | ALDH1A1GAAPOLB | |
| SCHEMBL22346510 | 0.81 | PABPC1 (0.39) | ALDH1A1GAAPOLBPABPC1PIK3CD | |
| SCHEMBL13036621 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GAAPOLBPIK3CDPIK3R1 | |
| SCHEMBL6101878 | 0.79 | PABPC1 (0.56) | ALDH1A1GAAPOLBPABPC1MEN1 | |
| SCHEMBL9924061 | 0.76 | PIK3CD (0.49) | ALDH1A1GAAPOLBPIK3CDPIK3R1 | |
| SCHEMBL25263244 | 0.76 | ALDH1A1 (0.44) | ALDH1A1GAAPOLBPIK3CDPIK3R1 | |
| SCHEMBL21772779 | 0.76 | FADS1 (0.40) | ALDH1A1GAAPOLBPABPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6936617-B2 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1406906-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003006471-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | ALDH1A1 797/4885GAA 2647/4885POLB 4332/4885 |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | ALDH1A1 553/4885GAA 2516/4885POLB 4266/4885 |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | ALDH1A1 991/4885GAA 583/4885POLB 2251/4885 |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | ALDH1A1 991/4885GAA 583/4885POLB 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.